Overview
Study of Telaprevir in Subjects With Hepatic Impairment
Status:
Completed
Completed
Trial end date:
2008-06-01
2008-06-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of this study is to assess the safety and pharmacokinetics of Telaprevir following administration of multiple oral doses to subjects with moderate and severe hepatic impairment.Phase:
Phase 1Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Vertex Pharmaceuticals Incorporated
Criteria
Inclusion Criteria:- Clinically diagnosed with Child Pugh score of 7-9 or greater than 10
- Women of non-childbearing age
Exclusion Criteria:
- Tested positive for HIV, Hepatitis C, Hepatitis B